University of Chicago Partners with Erick Lefkofsky
The doctors at the University of Chicago are receiving data to help treat breast cancer. This information is coming from Tempus, a new technology company that has created an operating system to help cancer patients.A partnership between the University of Chicago Medicine and Tempus was announced recently. Tempus will be providing molecular sequencing and analysis to specialists to help doctors to write personalized plans for the treatment of patients.The data will include data from over 1,000 patients with breast cancer. This data will be used to uncover patterns of responses to treatment.
Dr. Olufunmilayo Olopadeis, who is a dean at the University of Chicago, reports there is little data about the most common form of cancer.He is excited about the amount of information Tempus can provide about this dangerous disease because he believes it will significantly advance how doctors treat breast cancer patients. This information will also provide data to be studied by the University of Chicago.Tempus can provide this information by using a genomic sequencing.
Tempus has created many such partnerships with companies such as Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Rush University Medical Center, University of Michigan, the Mayo Clinic, and Penn Medicine. Tempus was founded in 2015 by Eric Lefkofsky.Eric Lefkofsky is also a co-founder of Groupon and Uptake Technologies. Uptake Technologies is an analytics platform for some of the world’s largest companies. Lefkofsky started the Lefkofsky Family Foundation in 2006.His wife, Liz, was part of this foundation that wanted to change lives in communities by advancing high-impact initiatives. Lefkofsky earned his Bachelor’s degree from the University of Michigan. He later received his Juris Doctor from University of Michigan Law School.He uses this degree as an adjunct professor at the University of Chicago. In his spare time, he writes and his book Accelerated Disruption is available now.
If you want to read the full article please: Click here.
Comments are closed.